HCG

November 10, 2022 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, Subject : Investor Presentation Stock Code : BSE – 539787, NSE – HCG We wish to inform you that the Board of Directors of the Company, at their meeting held on November 10, 2022, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2022. In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2022. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED INVESTOR PRESENTATION November 2022 SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This presentation has been prepared by HealthCare Global Enterprises Limited (the "Company"). These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States. The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point. This presentation contains certain "forward looking statements". Forward‐looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward‐looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof. This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. 2 www.hcgel.com Overview One of the Largest1 provider of Cancer care in India under “HCG” brand Comprehensive cancer diagnosis and treatment services (offering radiation therapy, medical oncology and surgery) 222 comprehensive cancer centers (including Kenya) FERTILITY TREATMENT MULTI SPECIALITY • Integrated reproductive medicine services • 4 Multi-Speciality hospitals providing high-quality tertiary care • 7 fertility centers in Bengaluru & North India 1. In terms of the total number of cancer treatment centers licensed by AERB as of March 31, 2015 (Source: Government of India, Atomic Energy Regulatory Board); 2. Includes center in Kenya; Bhavnagar multispecialty also includes comprehensive cancer services hence included in CCC count; 3 www.hcgel.com Our Journey Acquired the 1st privately Bangalore Institute of Company’s name changed to owned comprehensive cancer 1st Comprehensive HCG Ahmedabad, 1st Oncology commences HealthCare Global center in Karnataka Cancer Care Center in privately owned operations Enterprises Pvt. Ltd. 1st private cancer center in Jharkhand Comprehensive Cancer India to introduce Cyclotron Care Center in Gujarat 1989 1998 2005 2005 2006 2007 2008 2009 2011 Company Entry into clinical 1st to introduce IGRT One of the 1st centers in India to incorporated as laboratory business technology in North introduce CyberKnife technology. Curie Center of through acquisition of India HCG Hubli, 1st center in North Oncology Triesta Sciences Karnataka to introduce IGRT Technology STRAND Divestment and HCG Chennai, 1st 1st center to 1st Indian Company 1st CyberKnife in Acquisition of Laboratory & Cancer Center to use introduce to set up Cancer entire western Clinical trial business revolutionary FFF Tomotherapy-H Center in Africa India Technology in India Acquisition of Suchirayu 2012 2013 2016 2016 2017 2018 2019 2020 2021 HCG Cuttack, 1st Listed on BSE HCG Kolkata to ~ USD 150 million equity Comprehensive Cancer and NSE launch 1st Investment from CVC Capital Center in Odisha Radixact in India 1st Digital PET CT in India 4 www.hcgel.com Pioneered Scalable Model for Comprehensive Cancer Care Largest oncology focused Marquee leadership team hospital chain with a pan 1 5 and experienced India network management Leveraging digital Comprehensive cancer care transformation to model with a focussed 2 6 strengthen patient and factory approach doctor engagement Implementing asset-light 33+ years of differentiated model for efficient capital care leading to superior 3 7 allocation and better patient outcomes returns Consistent track record of High growth trajectory with being first to launch state- 4 8 roadmap for margin of-the-art technology in expansion India 5 www.hcgel.com Largest Pan-India Oncology Hospital Chain Best-in-class cancer care by adopting globally acclaimed practices and state-of-the-art technology Largest cancer care network in India 33+ years of Clinical Excellence Center of Excellence (CoE) Emerging Cancer Care Centers Established Cancer Care Centers(1) Jaipur Ahmedabad Ranchi Baroda Kolkata Shareholding Pattern as of Sep’22 Bhavnagar Nagpur Cuttack Nashik Vishakhapatnam Mumbai (2) Gulbarga Public Ongole M S Ramaiah Nagar Shareholders 29% Hubli 58% Shimoga Vijaywada Kalinga Rao Road 13% Bangalore Dr. BS Ajai Kumar Double Road and family Chennai 6 (1) Established centers were operational before 2017; (2) Includes 1 in Kenya. Bhavnagar multispecialty also includes comprehensive cancer care and included in CCC count; (3) CCC –Comprehensive cancer care center, www.hcgel.com defined as offering surgical, medical and radiation oncology services onsite, along with diagnosis / PET CT as well in some cases; (4) Includes multispecialty beds; (5) New patient registrations in last 5 years in oncology One Stop Solution with Superior Clinical Expertise END-TO-END CANCER CARE SERVICES AT HCG Expertise in Handling Complex Cases(1) DIAGNOSTICS Physical Laboratory Digital Digital PET Examination Tests Pathology 4.5k+ Genomic based TREATMENT Chemo sessions Robotic Targeted Drug Chemotherapy Radiation(3) Surgery Therapy 4.3k+ Psycho- Endocrine Bone Marrow Immunotherapy CyberKnife Cases(2) oncology Therapy Transplant Nuclear Liver Pediatric Genomics 10.2k+ Medicine Transplant Oncology Organ Preservation Surgeries POST CARE Home Health Psychological Preventive 2.8k+ Patient Care Services Support Oncology Robotic Surgeries in Oncology Not available or outsourced at multi-specialty hospitals 7 (1) Cases handled in last 5 years; (2) Total CyberKnife cases performed till date www.hcgel.com (3) Apollo has only 13 centers providing radiation facilities in a network of 71 hospitals Unique Long-term Value Creation Opportunity in Single Specialty Healthcare 1 2 3 4 5 Market leadership in Integrated cancer care High entry barriers for Profitable scalable Poised for high growth high growth industry for patient retention differentiated care business model with limited capex 33+ years of patient Only Indian integrated Specialized technical Historically superior Turnaround in • • • • • trust cancer care chain knowledge patient outcomes emerging centers India’s largest Superior patient Rapidly evolving Proven scalable model High-capacity • • • • • oncology player outcomes with top-of- expensive technology –strong operational headroom the-mind brand recall KPIs Under-coverage in Hub and spoke model Asset Light • • • Cancer care is a cancer care • –high patient volume Advanced treatments expansion • lifetime association with high realizations Differentiated services Largest oncologist Ongoing digital • Potential risk for • • • with rapidly evolving network with high Cost optimization in transformation and patient families • technology doctor retention progress marketing initiatives 8 www.hcgel.com Focused Factory Approach is critical for Quality of Life Cancer requires specialized care available at focused players only, with emphasis on clinical expertise Cancer has Unique Solutions available only at HCG’s Focused Factory Challenges that Requires Comprehensive Cancer Approach for Most a Specialist Approach Care (CCC) Centers Effective CCC Chronic, recurring, complex and Personalized, patient-centric care and End-to-end and ancillary care solutions heterogeneous precision medicine Cancer is an enigma –can spread from Largest oncologist network with high SUPERIOR Sub-specialists by organ / modality source organ to other parts rapidly clinical expertise PATIENT OUTCOMES Multiple treatments and oncologists Ability to detect and treat advanced Tumor Board driven best practices with required by each patient forms of cancer focus on oncology related research ENSURING QUALITY OF Rapidly evolving landscape requiring Advanced technologies sourced via Fastest technology adoption with LIFE constant research focus global research and innovation flexibility to innovate ✓ ✓ ✓  OTHER CCCs MULTI-SPECIALTY   HOSPITALS 9 www.hcgel.com Dominant Network in Cancer Care with Market Leadership across 13 out of 18 Cities HCG is committed to provide last mile cancer care across India and is the largest player with >1.6x footprint of CCCs as compared to the next largest player METROS & NON-METROS MARKET LEADERSHIP ACROSS REGIONS(1) # of cancer Leader Across States centers : 21 ❖Karnataka ❖Jharkhand # of cancer ❖Gujarat ❖Odisha centers : 8 MULTIPLE METROS e Market Leadership across cities c n e s # of cancer ❖Ahmedabad ❖Ranchi e r P centers : 13 ❖Bangalore ❖Baroda c ❖Nashik ❖Shimoga ih p # of cancer ❖Nagpur ❖Gulbarga a r # of cancer g centers : 8 ❖Cuttack ❖Hubli o centers : 7 e G ❖Bhavnagar ❖Ongole SINGLE REGION ❖Vijayawada 3 Top 3 in other cities # of cancer ❖Jaipur ❖Vizag # of cancer # of cancer centers : 7 centers : 1 centers : 1 Bubble size represents the - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 number of Cancer Care Centers Revenue from Oncology(2)(INR mn) 10 (1) Market position by revenue based on management estimates. For private oncology players only (excluding trusts, governmenthospitals); (2) FY21 revenue for Tata Memorial Hospital -Mumbai, Apollo Hospitals and www.hcgel.com Omega Hospitals; FY22 revenue for all others. Note: Oncology share is assumed to be 100% for Tata Memorial and Omega Hospitals. For Apollo Hospitals, only hospital revenue (Healthcare Services) is considered Successfully Decoded Non-metro Business Model MARKET LEADER IN ALMOST 9 NON-METRO CENTERS WITH SUCCESSFUL SCALABLE ALL NON-METRO CENTERS HIGH-TEEN ROCE NON-METRO MODEL Jaipur 13 12 9 9 Baroda Ranchi Nagpur Key Parameters(1) Metro Non-Metro Cuttack Bhavnagar Nashik Vishakhapatnam Gulbarga Revenue CAGR(2) 18% 17% Hubli Ongole Vijaywada Shimoga Average EBITDA % 25% 23% All Non- >15% >20% Market Leadership (11) > 15% Payor Mix(3) 84% 52% Metro EBITDA EBITDA ROCE(1) Top 3 in other Non-metro Centers (2) Centers Margin Margin 11 Note: Figures for H1’23; (1) For established centers only; (2) CAGR between FY20 –H1’23; (3) Payor mix for cash, insurance and corporate, excluding government scheme related patients www.hcgel.com Leveraging Digital Transformation to Reshape Patient and Partner Engagement KEY DIGITAL TRANSFORMATION IMPERATIVES FOR HCG 2.0 Increasing reach and Omnichannel patient Ecosystem of digital Integrated patient- Improving customer Digitalized post awareness engagement healthcare lifecycle management convenience discharge engagement Transforming Patient Journey - Optimizing Engagement Cloud Telephony E-Prescription Seamless tracking of offline Doctor platform; access to leads; auto-dialer for lower TAT; medical history; captures chief controls for handling missed calls 02 04 complaints, diagnosis etc. 01 03 05 Patient Application Business Intelligence Self service tool for Unified single data repository; appointments, consultations, analytical models; real time CRM medicines and patient insights into the business engagement 360°patient view; omni-channel interface; real time lead visibility; better lead management 12 www.hcgel.com Successful Playbook of Smart Acquisitions and Driving Sustained Growth Post Integration Time tested and highly replicable model of consistent revenue growth and profitability across geographies HCG Ahmedabad (Metro City) HCG Cuttack (Non-metro City) Acquisition 2013(1) 2008 Year Revenue c. 22% c. 38% CAGR(2) Margin > 1,000 bps > 1,000 bps Expansion(2) Scaled and maintaining #1 market Significantly upgraded technology position for over 5 years far superior to the market Key Interventions Substantially developed clinical Deep penetration into large expertise and technology to untapped catchment ensuring transform into regional CoE continuing 1stmover advantage 13 (1) HMS (multispecialty) was acquired in 2007 but the comprehensive cancer care unit –HCC was demerged in 2013; (2) Till FY22 www.hcgel.com Well Poised to Outpace Industry Growth Visible growth opportunities supported by proven brand-driven play, professional approach and ready capacity A ▪ Strong growth across regions aided by market leadership and high incidence growth Demand Driven ▪ Existing facilities have significant capacity to support the growth Consistent Growth in Digital ▪ Management led initiatives to boost digital presence and integrate end-to-end patient Strong business Existing Business Transformation engagement; driving higher growth and better realizations and returns profile with deeper market International ▪ Focus on expanding international presence and increasing revenue share in attractive Medical Tourism geographies penetration B Brownfield / ▪ 6 LINACs in pipeline (own + pay per use) over next 1-2 years to augment capacity in high growth regions Greenfield Expansion ▪ Ongoing greenfield expansion at Ahmedabad and Bangalore by adding 125 beds cumulatively At the right inflection point to scale-up through additional business adjacencies C Inorganic ▪ Playbook of making smart acquisitions and driving sustained growth post integration -only realistic buyer for Expansion standalone cancer hospitals in India; successful track record of acquiring and scaling hospitals Potential incremental D Clinical Trials ▪ Very low existing scale with 3-4 years of experience; finalizing business plans for significant expansion growth & Diagnostics(1) ▪ Capital adjacent opportunity; high potential to expand EBITDA without significant capex Capital Light Capital Led 14 (1) While clinical trials and diagnostics are existing business lines, the company has not invested in the same in the last 3-4 years. The management plans to prudently invest to grow these businesses going forward www.hcgel.com High Revenue Growth with Well-diversified Segments Expansive Geographical Presence(1) Diversified Revenue from Various Modalities(1) 3%Others(2) Others 2% Maharashtra Metros Karnataka 16% Out-patients 34% 53% 18% Medical 37% Revenue by Revenue by Oncology 20% Cluster City Type AP + East 47% 18% Radiation Non- 27% Oncology Metros 25% Gujarat & Surgical Rajasthan Oncology Emerging Center Turnaround Ramp Up of Emerging Centers: Revenue contribution by EBITDA -19% -6% 4% 10% Emerging Centers increasing consistently Margin % Total 10% 13% 16% 15% Low Geographical Risk: Diverse geographical spread Revenue reducing revenue concentration and dependence 2.9x s r ) n 2,439 em t Multi-Modality: Revenues spread across modalities n R 1,870 e C N reducing concentration risk further g n I ( e 1,049 ig u n 856 Not Constrained by Beds: Significant Revenue not r ee mv e dependent on in-patient beds; Surgical oncology & partial ER Medical oncology requires in-patient beds FY20 FY21 FY22 Annualized H1'23 15 (1) For H1’23; (2) Includes Chennai and Kenya www.hcgel.com Revenues includes only Oncology business Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion Capital efficient growth driven by 18-20% ROCE breakup from Cancer Centers expansion in clinical trials and diagnostics Vintage Pre-Corp. Post-Corp. Ongoing value Established 25% 20% creation projects in Medium-term Centers digitalization and ROCE Target Emerging cost optimization (4%) (8%) Centers measures 11% Margin expansion Asset light due to operating expansion through leverage day care beds, hub & ROCE spoke operations H1’23 Emerging centers to and pay per use for ramp up to full equipment High growth potential potential in current business aided by sufficient capacity headroom 16 www.hcgel.com Strong Financial Profile with Low Leverage and Reduced Capex Needs Capex ▪ Low future capex 2,873 2,115 1,265 354 704 629 (INR mn) requirements ▪ Focus on optimizing 35% existing infra and Capex 22% brownfield projects (INR mn) 12% 8% 3% 5% ▪ Ongoing capex for two greenfield expansions -INR FY18 FY19 FY20 FY21 FY22 H1'23 186 mn (balance in FY23) and INR 836 mn (FY24) Capex % of Revenue 3.4x 1.1x 0.8x 0.8x 12,798 ▪ Significant deleveraging in Net Debt 6,520 7,940 6,972 7,076 the past few years (INR mn) 2,882 1,901 2,113 ▪ Comfortable debt position 6,278 with wellcapitalized 5,058 5,070 4,963 balance sheet FY20 FY21 FY22 H1'23 Capital Leases (IND AS 116) Net Debt 17 www.hcgel.com Proven Track Record of Outperforming the Industry Expansion Phase Ramp Up Phase CAGR 15% ▪ Consistently upward 16,561 revenue trajectory CAGR 19% 13,978 ▪ Expansion mode by 10,956 9,787 10,134 setting up new cancer Revenue 8,307 7,001 (INR mn) 5,842 centres till FY19 to achieve large scale ▪ Demonstrated high growth post Covid (1) FY16 FY17 FY18 FY19 FY20 FY21 FY22 Annualized across centres H1'23 Expansion Phase Ramp Up Phase ▪ Strong improvement in CAGR 19% profitability 3,200 2,937 25% ▪ Subdued in expansion 2,700 2,380 phase due to setting up EBITDA(2) CAGR 14% 20% 2,200 1,722 new centres (INR mn) 1,700 848 1,050 1,188 1,252 1,266 17% 18% 15% ▪ Significant scale 1,200 16% benefits; outpacing 14% 700 15% 15% 13% 12% 10% revenue due to 200 operating leverage (300) 5% FY16 FY17 FY18 FY19 FY20 FY21(1) FY22 Annualized H1'23 18 (1) FY21 and H1’22 impacted due to covid-related headwinds www.hcgel.com (2) EBITDA, post-corporate expenses. EBITDA for FY20-FY22 is after IND AS 116 adjustments Improved Performance Leading to Profitability 2.2x 4,081 4,200 3,520 3,581 3,646 Revenue 2,740 2,981 3,231 2,479 1,935 (INR mn) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 3.9x 300 722 747 EBITDA 617 619 633 194 512 (INR mn) 378 394 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 +ve PAT (398) (223) (292) 1,031 (458) 60 61 74 (INR mn) (Post IND-AS (1,022) (96) 116) (1) (2) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 +ve PAT (333) (158) (229) (60) 1,067 (424) 94 92 105 (INR mn) (958) (Pre IND-AS 116) (1) (2) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 19 (1) Includes loss due to exceptional items of INR 847 mn www.hcgel.com (2) Includes gain on exceptional items of INR 1,401 mn Led by Board of Directors comprising of Industry Veterans Dr. BS Ajai Kumar Siddharth Patel Executive Chairman Non-Executive Non-Independent Director Visionary and key driving force of HCG, with an Partner at CVC. 20+ years of leading successful aim to make advanced cancer care accessible investments across sectors globally Raj Gore Amit Soni Whole-time Director and CEO Non-Executive Non-Independent Director Seasoned healthcare leader with 20+ years in Partner at CVC. 15+ years of investment management across North America, Asia & Africa experience including General Atlantic and 3i Abhay Prabhakar Havaldar Anjali Ajaikumar Rossi Non-Executive Independent Director Executive Director - Strategy Established General Atlantic’s India Office. Board Social entrepreneur with over 12+ years in member of Jubilant Foodworks, IBS Software etc. healthcare; focused on quality and strategy Geeta Mathur Jeyandran Venugopal Non-Executive Independent Director Non-Executive Independent Director Experienced finance professional, serving on 20+ years in technology & product innovation; Boards of India Infoline, Sentiss Pharma etc. Currently Chief Product Officer Flipkart Rajagopalan Raghavan Pradip Kanakia Non-Executive Independent Director Non-Executive Independent Director 30+ years of leadership experience. Currently 36+ years in audit and governance. On the serving as Head of HR at Indigo Airlines Board of JM Financial, Camlin Fine Science etc. 20 www.hcgel.com Marquee Management Team supported by Experienced Promoters SEASONED PROMOTERS – LEADING VALUE CREATION Dr. BS Ajai Kumar CVC Capital Partners Founder and Executive Chairman Promoters & Board Members • Served as the CEO from 2005 to 2021 • Large portfolio of marquee healthcare • Over 40+ years of experience in practicing investments globally of c. USD 12 bn+ oncology in India and US Significantly Expanded Management Team with Senior Healthcare Professionals Srinivasa Dr. Bharat Ashutosh Sapna Agarwal Madan Stuti Jain Raj Gore Deepti Tewari Sudeep Dey Vineesh Ghei Raghavan Gadhavi Kumar Head of Sampath Head CEO Head HR CIO Head Sales CFO Head-Gujarat Strategy Operations Supply Chain Marketing 20+ 25+ 20+ 20+ 13+ 20+ 25+ 15+ 15+ 15+ New Hires since 2020 Existing Management 21 Total years of experience www.hcgel.com Q2 & H1FY23 FINANCIAL & OPERATIONAL HIGHLIGHTS SUBASENI LENKA, CANCER WINNER I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 22 www.hcgel.com Financial Highlights Q2 FY23 REVENUE REVENUE - HCG Centers (1) REVENUE - Milann Centers^ +19% +21% +15% 4,200 4,035 166 3,520 3,346 144 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Q2FY22 Q2FY23 ADJUSTED EBITDA PROFIT AFTER TAX2 PROFIT AFTER TAX2 ADJUSTED EBITDA MARGIN (Pre-IND AS) (Post-IND AS) +28% +130 bps +137% +790% 810 19.3% 105 74 18.0% 633 44 8 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Adjusted EBIDTA excludes - Impact of ESOPs cost of INR 12.9 mnfor Q2FY23 and 15.5 mnin Q2FY22 & - Impact of one-time consulting fees for strategy work for a period of 12-18 months. Cost of one-time consulting fees stands at INR 50.2 mm for Q2FY23 23 1. 22 comprehensive cancer centers, 3 multispecialty hospitals ^Q2FY22 revenues for Milann are excl for covid vaccinations Rs in Mn www.hcgel.com 2. PAT for Q2FY22 is pre-exceptional items Financial Highlights H1 FY23 REVENUE REVENUE - HCG Centers (1) REVENUE - Milann Centers^ +23% +23% +32% 8,281 7,942 338 6,751 6,456 257 H1FY22 H1FY23 H1FY22 H1FY23 H1FY22 H1FY23 ADJUSTED EBITDA PROFIT AFTER TAX2 PROFIT AFTER TAX2 ADJUSTED EBITDA MARGIN (Pre-IND AS) (Post-IND AS) +40% +230 bps 1,566 18.9% Turns 197 Turns 134 16.6% 1,121 Positive Positive H1FY22 H1FY23 H1FY22 H1FY23 -15 -87 H1FY22 H1FY23 H1FY22 H1FY23 Adjusted EBIDTA excludes - Impact of ESOPs cost of INR 31.5 mnfor Q2FY23 and INR -8.6 mnfor H1FY22 & - Impact of one-time consulting fees for strategy work for a period of 12-18 months. Cost of one-time consulting fees stands at INR 65.5 mm for H1FY23 24 1. 22 comprehensive cancer centers, 3 multispecialty hospitals ^H1FY22 revenues for Milann are excl for covid vaccinations Rs in Mn www.hcgel.com 2. PAT for H1FY22 is pre-exceptional items Growth Across HCG Centers Matured Centers Emerging Centers^ ~1.6x ~2.0x growth in last 8 quarters growth in last 8 quarters +19% +26% # E 2,979 3,090 929 945 U 2,596 2,628 2,663 785 826 N 2,304 2,418 693 750 E 1,890 2,100 V 479 509 535 E R Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Matured Centers Emerging Centers^ ~2.0x On a positive trajectory growth in last 8 quarters +20% +186% * A 750 777 100 95 D 645 654 676 76 606 T 549 I B 477 33 37 394 E 5 8 -3 -21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 25 Rs in Mn *Excl. Corporate Expenses ^Emerging Center represents centers operational after 2017 #Excl. Revenue & EBIDTA for Fertility www.hcgel.com HCG – Q2FY23 Operational Metrics# MATURED CENTERS EMERGING CENTERS MATURED CENTERS TOTAL AOR (%) AOR (%) AOR^* (%) ROCE (%) 66.4% 65.0% 69.9% 20.0% 56.1% in Q2FY22 57.6% in Q2FY22 51.8% in Q2FY22 15.4% in FY22 1,030 bps 740 bps 1,810 bps 460 bps ROCE pre-corporate allocations stands at 24.8% MATURED CENTERS EMERGING CENTERS EMERGING CENTERS^ TOTAL ARPOB (Rs.) ARPOB (Rs.) ARPOB^ (Rs.) ROCE (%) 36,914 39,684 30,145 -4.9% 36,437 in Q2FY22 37,667 in Q2FY22 33,942 in Q2FY22 -8.3% in FY22 1.3% 5.4% 11.2% 340 bps ROCE pre-corporate ^New Center represents centers operational after 2017 allocations stands at -0.9% *72% of the total capacity beds are operational; AOR 57% on capacity beds #Excl. Fertility Revenue 26 Existing Centers Operational beds: 1302 + New Centers Operational Beds: 495 = Total 1,797 Operational Beds www.hcgel.com ROCE is H1FY23 annualized HCG – Cluster Wise Revenue Break Up# CLUSTER Q2FY23 Q2FY22 Y-o-Y H1FY23 H1FY22 Y-o-Y KARNATAKA 1,425.8 1,128.9 26.3% 2798.8 2239.6 25.0% GUJARAT 1,052.9 879.4 19.7% 2053.6 1748.2 17.5% MAHARASHTRA 564.7 642.2 -12.1% 1164.9 1188.8 -2.0% EAST INDIA 401.6 302.9 32.6% 789.0 555.1 42.1% ANDHRA PRADESH 299.8 258.8 15.8% 596.7 501.0 19.1% TAMIL NADU 67.4 65.8 2.5% 127.4 107.8 18.2% NORTH INDIA 207.0 67.9 204.7% 380.7 115.7 229.0% AFRICA 15.2 - - 31.2 - - TOTAL 4,034.5 3,345.9 20.6% 7,942.3 6,456.4 23.0% BANGALORE JAIPUR RAJKOT RANCHI KOLKATA MUMBAI* COE 205% 80% 60% 40% 35% 30% Y-o-Y Y-o-Y Y-o-Y Y-o-Y Y-o-Y Y-o-Y for Q2FY23 For Q2FY23 For Q2FY23 For Q2FY23 For Q2FY23 For Q2FY23 Market position for private oncology markets only (excluding trusts, government hospitals), based on management estimate; 1. Includes Multispecialty Beds 27 #Excl. Fertility Revenue Rs in Mn www.hcgel.com *Excl. Vaccination revenue Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Growth Particulars Q2FY23 Q2FY22 H1FY23 H1FY22 Y-o-Y Y-o-Y New Registrations 1,152 1,014 13.6% 2,764 1,690 63.6% M S Ramaiah Nagar Shivananda IVF Cycles 473 431 9.7% 1,011 742 36.3% Indiranagar Revenues* Whitefield 165.5 144.3 15.4% 338.2 257.0 31.6% (Rs. Mn.) JP Nagar Emerging Centers Good recovery demonstrated in H1FY23 across all metrics Matured Centers (1) • Continued effort on digital campaigns have resulted growth in new registrations NORTH INDIA (2 Centers) • Continuous focus on strengthening clinical talent Chandigarh Looking to focus on market leadership in Bangalore and scaling up North India centers in near term Delhi 28 *Q2FY22 & H1FY22 revenues for Milann are excl for covid vaccinations 1. Centers in operation prior to April 1, 2016, i.e., Shivananda, JP Nagar and Indiranagar www.hcgel.com Capital Expenditure & Net Debt CAPITAL EXPENDITURE (Rs. Mn.) NET DEBT (Rs. Mn.) NET DEBT 30th Sep 2022 31st March 2022 HCG CENTERS H1FY23 FY22 Bank Debt(1) 3,485 3,543 Vendor Finance(2) 205 333 Matured Centers 581 458 Other Debt 20 34 Less: Cash & Cash Equivalents(3) (1,598) (2,008) Emerging Centers 49 246 NET DEBT 2,113 1,901 TOTAL CAPEX 629 704 Capital Leases: Ind AS116 4,963 5,070 Net Debt (Incl. Leases) 7,076 6,972 ONGOING CAPEX (Rs. Mn.) Expected Capex Capex incurred till Expected Capex Total Planned Expected date of Sr. No Particulars between Oct 22 to 30th Sep 2022 for FY24 Capex Operations Mar 23 1 Ahmedabad – Phase II 70.0 146.2 635.8 852.0 Q1 FY25 Whitefield (Extension of 2 10.0 40.0 200.0 250.0 Q4 FY24 Bangalore - COE) 1. Bank debt: Net of Bank balance held as margin money of INR 147 Mn and investment in fixed deposits of INR 182 Mn as of 30th Sep -22, margin money of INR 147 Mn and investment in fixed deposits of INR 99 Mn as of 30th June-22. The unamortized portion of processing fees amounting to INR 30 Mn as on 30th Sep -22 & INR 32 Mn as on 31st June -22 netted off against Bank Debt. 2. Vendor Finance; Includes Forex reinstatement of INR 6.39 Mn as of 30th Sep-22 and Forex reinstatement of INR 5.00 Mn as of 30th June-22 3. Cash and cash equivalents: Includes investment in mutual funds of INR 16 Mn as at 30th Sep -22 and of INR 16 Mn as at 30th June-22 29 www.hcgel.com Q2 & H1 FY23 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q2 FY23 Q2 FY22 Y-o-Y Q1 FY23 Q-o-Q H1 FY23 H1 FY22 Y-o-Y Revenues from Operations 4,192.1 3,512.5 4,073.1 8,265.2 6,736.7 Income from Govt. Grant 7.9 7.1 7.4 15.3 14.3 Total Revenue from Operations 4,200.0 3,519.6 19.3% 4,080.5 2.9% 8,280.5 6,751.0 22.7% Cost of Goods Sold 1,023.6 912.1 978.0 2,001.6 1,743.5 Employee Cost 670.4 545.7 668.5 1,338.9 1,127.8 Medical Consultancy Charges 897.9 699.0 866.7 1,764.6 1,369.9 Other Expenses 798.1 729.9 811.9 1,609.9 1,388.7 Adjusted EBITDA 810.0 632.9 28.0% 755.4 7.2% 1,565.5 1,121.1 39.6% Adjusted EBITDA Margin (%) 19.3% 18.0% 130 bps 18.5% 77 bps 18.9% 16.6% 230 bps One time value creation cost 50.2 0.0 15.3 65.5 ESOP’s 12.9 15.5 18.6 31.5 -8.6 Reported EBIDTA 746.9 617.4 21.0% 721.5 3.5% 1,468.5 1,129.7 30.0% Reported EBITDA Margin (%) 17.8% 17.5% 24 bps 17.7% 10 bps 17.7% 16.7% 95 bps Depreciation 408.3 380.2 396.7 805.0 758.0 Other Income 19.7 33.0 29.1 48.8 67.4 EBIT 358.3 270.2 32.6% 353.9 1.3% 712.3 439.1 62.2% Finance Cost 258.1 232.3 249.8 507.9 496.1 Extraordinary Items 0.0 1,401.2 0.0 1,401.2 Share in Profit/(loss) in JV and Associates 0.0 -20.0 0.0 0.0 -14.3 Profit before Tax 100.2 1,419.1 104.1 204.4 1,329.9 Taxes, Other Comprehensive Income & 26.4 388.2 43.6 70.1 394.7 Minority Interest Profit After Tax 73.8 1030.9 60.5 134.3 935.2 PAT Margin (%) 1.4% 27.5% 0.8% 1.1% 12.8% EPS 0.5 8.2 0.4 1.0 7.5 30 www.hcgel.com Consolidated Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Sep-22 Mar-22 Balance Sheet - Assets (Rs. Mn.) Sep-22 Mar-22 Equity Share Capital 1,391 1,390 Non-Current Assets Other Equity 7,420 7,313 Property, Plant And Equipment 9,166 9,315 Equity Attributable To Equity Holders Of The 8,810 8,703 Capital Work in Progress 629 217 Company Non-Controlling Interests 92 134 Rights-of-use Assets 3,807 4,045 Total Equity 8,902 8,837 Goodwill 1,813 1,813 Non-Current Liabilities Other Intangible Assets 243 298 Financial Liabilities Intangible Assets Under Development 31 30 Borrowings 3,732 3,629 Financial Assets Lease Liabilities 4,481 4,659 Investments 58 58 Other Financial Liabilities Loans Receivable 0 0 Provisions 112 105 Other Financial Assets 699 546 Other Non-Current Liabilities 323 255 Deferred Tax Assets (Net) 54 60 Deferred Tax Liabilities (Net) 58 13 Total Non-Current Liabilities 871 866 Income Tax Assets (Net) 638 459 Current Liabilities Other Non-Current Assets 221 331 Financial Liabilities Total Non-Current Assets 17,357 17,172 Borrowings 309 448 Current Assets Lease Liabilities 483 411 Inventories 375 300 Trade Payables Financial Assets Total Outstanding Dues Of Micro Enterprises And 37 20 Trade Receivables 2,667 2,175 Small Enterprises Total Outstanding Dues Of Creditors Other Than Cash And Cash Equivalents 1,590 1,975 2,266 1,919 Micro Enterprises And Small Enterprises Bank Balances Other Than Cash And Cash Equivalents 1 0 Other Financial Liabilities 1,003 936 Loans 18 16 Other Current Liabilities 808 785 Other Financial Assets 356 341 Provisions 192 173 Other Current Assets 349 217 Income Tax Liabilities (Net) 9 5 Total Current Liabilities 5,106 4,698 Total Current Assets 5,356 5,024 Total Equity And Liabilities 22,713 22,195 Total Assets 22,713 22,195 31 www.hcgel.com Consolidated Cash Flow Statement Cash Flow Statement (in Rs. Mn) Sep-22 Sep-21 Net Profit Before Tax 204 1,330 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 1,380 -163 Operating Profit Before Working Capital Changes 1,585 1,167 Changes In Working Capital -379 -288 Cash Generated From Operations 1,206 879 Direct Taxes Paid (Net Of Refund) -250 -86 Net Cash From Operating Activities 956 793 Net Cash From Investing Activities -706 809 Net Cash From Financing Activities -640 -1,948 Net Increase/Decrease In Cash And Cash Equivalents -390 -346 Add: Cash & Cash Equivalents At The Beginning Of The Period 1,927 29 Cash & Cash Equivalents At The End Of The Period 1,537 -318 32 www.hcgel.com HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 33 www.hcgel.com Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY22 FY21 FY20 FY19 CAGR Revenues from Operations 13,948 10,092 10,923 9,760 Income from Govt. Grant 30 43 33 27 Total Revenue from Operations 13,978 10,134 10,956 9,787 13% Costs of Goods Sold 3,549 3,632 3,645 3,581 Employee Cost 2,337 1,959 2,080 1,845 Medical Consultancy Charges 2,958 2,218 2,451 2,114 Other Expenses 2,754 2,289 2,305 2,389 EBITDA 2,380 1,266 1,722 1,252 24% EBITDA Margin (%) 17.0% 12.5% 15.7% 12.8% Depreciation 1,583 1,592 1,485 851 Other Income 127 170 70 74 EBIT 924 -157 307 475 25% Finance Cost 978 1,192 1,377 699 Extraordinary Items 946 -847 0 0 Share in Profit/(loss) in JV and Associates -14 -4 -123 -110 Profit before Tax 878 -2,199 -1,193 -334 - Taxes, Other Comprehensive Income & Minority Interest 340 -264 -131 -86 Profit After Tax 538 -1,935 -1,062 -248 - PAT Margin (%) 3.8% -19.1% -9.7% -2.5% EPS (in INR) 4.1 -16.9 -2.9 -2.8 34 www.hcgel.com Historical Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 1,390 1,254 887 879 Other Equity 7,313 5,718 2,926 3,933 Equity Attributable To Equity Holders Of The Company 8,703 6,972 3,813 4,811 Non-Controlling Interests 134 168 385 619 Total Equity 8,837 7,140 4,198 5,430 Non-Current Liabilities 0 0 0 0 Financial Liabilities 0 0 0 0 Borrowings 3,629 3,462 5,296 4,666 Lease Liabilities 4,659 4,693 6,092 202 Other Financial Liabilities 255 0 624 0 Provisions 105 86 73 56 Other Non-Current Liabilities 0.0 280 422 318 Deferred Tax Liabilities (Net) 13 43 70 43 Total Non-Current Liabilities 8,661 8,564 12,576 5,285 Current Liabilities 0 0 0 0 Financial Liabilities 0 0 0 0 Borrowings 448 670 937 648 Lease Liabilities 411 365 215 0.0 Trade Payables 0 0 0 0 Total Outstanding Dues Of Micro Enterprises And Small Enterprises 20 3 0 0.0 Total Outstanding Dues Of Creditors Other Than Micro Enterprises 1,919 1,452 1,536 1,683 And Small Enterprises Other Financial Liabilities 936 1,428 2,654 2,557 Other Current Liabilities 785 626 305 337 Provisions 173 104 91 63 Income Tax Liabilities (Net) 5 4 22 12 Total Current Liabilities 4,698 4,653 5,758 5,300 Total Equity And Liabilities 22,195 20,356 22,532 16,015 35 www.hcgel.com Historical Balance Sheet Balance Sheet - Assets (in Rs. Mn.) Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, Plant And Equipment 9,315 8,531 9,271 8,026 Capital Work in Progress 217 300 461 1,440 Rights-of-use Assets 4,045 4,114 5,776 0 Goodwill 1,813 963 1,093 1,093 Other Intangible Assets 298 215 320 96 Intangible Assets Under Development 30 206 268 469 Financial Assets 0 0 0 0 Investments 58 57 74 68 Loans Receivable 0 451 516 476 Other Financial Assets 546 168 222 196 Deferred Tax Assets (Net) 60 343 261 311 Income Tax Assets (Net) 459 426 818 307 Other Non-Current Assets 331 232 414 742 Total Non-Current Assets 17,172 16,007 19,494 13,222 Current Assets 0 0 0 0 Inventories 300 211 233 285 Financial Assets 0 0 0 0 Trade Receivables 2,175 1,866 1,857 1,646 Cash And Cash Equivalents 1,975 300 318 280 Bank Balances Other Than Cash And Cash Equivalents 0 109 3 44 Loans 16 93 54 40 Other Financial Assets 341 1,546 275 211 Other Current Assets 217 225 300 288 Total Current Assets 5,024 4,350 3,038 2,793 Total Assets 22,195 20,356 22,532 16,015 36 www.hcgel.com Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-22 Mar-21 Mar-20 Mar-19 Net Profit Before Tax 878 -2,287 -1,193 -334 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 1,666 3,619 2,988 2,463 Operating Profit Before Working Capital Changes 2,543 1,333 1,795 2,130 Changes In Working Capital -105 -507 -226 -774 Cash Generated From Operations 2,438 826 1,569 1,355 Direct Taxes Paid (Net Of Refund) -237 380 -267 370 Net Cash From Operating Activities 2,201 1,205 1,301 985 Net Cash From Investing Activities 1,246 -1,711 -1,014 -2,382 Net Cash From Financing Activities -1,549 1,123 -584 835 Net Increase/Decrease In Cash And Cash Equivalents 1,898 617 -297 -562 Add: Cash & Cash Equivalents At The Beginning Of The Period 29 -588 -291 271 Cash & Cash Equivalents At The End Of The Period 1,927 29 -588 -291 37 www.hcgel.com Vision, Mission and Values VISION MISSION Adding life to years by redefining To be an acclaimed healthcare institution healthcare through global in pursuit of medical excellence through innovation value-based medicine VALUES Quality Collaboration Innovation Integrity Leadership Enabling Limitless Innovative We are honest, We strive to be the patients to possibilities of ways to forthright and best at what we achieve collaborative ensure better are responsible do, both as a better lives energy and medical corporate company and as teamwork outcomes citizens individuals 39 www.hcgel.com Select Awards and Accreditations Leading Oncology Brand with Industry Wide Recognition in 2020-21 Accreditations Leader in Oncology Best Cancer Care Hospital Chain All India Critical Care Hospital Ranking Navbharat Healthcare Award -HCG Survey 2020 –HCG Bangalore Mumbai & Nagpur Top Specialized – Best Hospitals Nursing Excellence HCG Ahmedabad has been listed by Association of Healthcare Providers The News Week -India (AHPI) Award Best Cancer Hospital Group Ranked 1st Best Cancer Hospital –HCG Andhra Pradesh Ranked 1stby All India Critical Care Center of Excellence for Oncology –HCG, Kolkata Hospital Ranking Survey 40 Note: Not an exhaustive list www.hcgel.com Setting Standards in ESG for conserving Natural Capital Pioneer among hospitals to adopt Integrated Reporting (IR) Framework in FY19, with disclosures covering performance against Financial, Manufactured, Social, Intellectual, Natural & Human Capital Key Practices for Environment Conservation Enhancing Water Use Energy Optimization and Efficiency Emission Reduction Implementing ESG policy and standards Monitoring of water Reduction in paper consumption using water consumption in FY 2020-21 by meters at discharge 74% points Assessing the impact of operations on the environment ESG Initiatives Raising awareness and initiating behavioral changes Auditing community contributions & sustainability Proper Waste Increase in Renewable Management Energy Consumption Medical waste treatment Solar rooftop capacity: 1,593 Reviewing progress and evaluating the environmental facility, authorized by KVA management system, as and when needed SPCB(1) 41 Note: (1) State Pollution Control Board www.hcgel.com Enduring Patient Trust for 33+ Years “We’re getting treated in this hospital for last 4 months. Radiation, surgery & now chemo INTEGRATED CARE treatment is going on. We’re satisfied with all the services and treatments” -Krishna Murthy “Almost every institute gave up. Finally, HCG made it happen and I Couldn’t be happier! It’s MANAGING been 8 years now and I’m living a normal life” COMPLEX CASES -Savita Devi “Each member of the staff, right from the doctors to the cleaning staff have gone out of their PERSONALIZED way to help my husband in every possible way” PATIENT-CENTRIC -Rose Pani “My son was diagnosed with Lymphoblastic Leukemia. HCG assured us that our son’s condition MODALITY was curable with proper treatment and care. With each passing day, my son is doing better. ” SPECIALISTS -Heeramani Mohanta “The vast knowledge and expertise of the doctors gave me and my family enormous confidence TECHNOLOGY to go ahead with the Cyberknife treatment. I am thankful to HCG for saving my life” LEADERSHIP -Harshana Rajani 42 www.hcgel.com Oncology Market in India SARITA DEVI, CANCER WINNER I chose the hospital that said my cancer could be treated over the hospital that said I only had six months 43 www.hcgel.com High Patient Volume driving Oncology Growth in India Under-coverage of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 3% 263 38% 10% 1% India China UK USA 3% Realization Affordability Population coverage by national cancer registries 3% Relapse Driven Increasing Cancer Incidences in India 1% 151 Cancer Population Incidences Growth 5,500 4,000 3,000 1,700 2020 2030 2019 2024 Reported Incidences ('000s) Real Incidences ('000s) 44 Sources: Globacan 2018, ICMR; NCRP Annual Report 2020, Industry Reports www.hcgel.com High Growth Headroom due to Low Population Coverage Low Early-stage Diagnosis in India … …leading to High Mortality to Incidence Ratio 88% 91% 81% 71% 73% 70% 61% 51% 52% 56% 29% 31% 30% 19% 31% 26% 25% 15% 17% 22% 28% 23% 33% 8% Breast Cancer Head and Neck Lung Cancer Breast Cancer Head and Neck Lung Cancer USA UK China India USA UK China India Majority of the Comprehensive Cancer Centers …but Non-Metros to Grow Faster than Metros concentrated in Metros… mainly driven by Volume Growth (FY19-FY24) 15% Top 8 Metros(1) 12% 12% 30% 8% 4% 60% 3% Rest of India 10% Other State Capitals Volume Growth Realization Growth Total Growth Metros Non-Metros 45 Sources: “List of Cancer Treatment Centers licensed by AERB”, aerb.gov.in, Feb 2021; “Population of India as per census 2011”, Censusindia.gov.in; Industry reports www.hcgel.com (1) Top 8 metros include Delhi, Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Pune and Ahmedabad QUALITY FOCUSED SHANKAR, CANCER WINNER The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 46 www.hcgel.com Many Firsts of Cutting-edge Technology Introduction for Integrated Cancer Care 1st State-of-the-art Equipment in each modality TRACK RECORD OF BEING TO LAUNCH ADVANCED TECHNOLOGY IN DIAGNOSTICS Total PET CTs : 17 INDIA AI-based 2022 RIS PACS Automated Ethos / Skyra Digital PET Digital Breast Digital Molecular / Tesla 3T 2022 Adaptive CT Pathology Volume Mammography Genomics lab for MRI Radiation Scanner Radixact 2018 RADIOTHERAPY Total LINACs : 30 2016 Tomotherapy - H Genomics 2013 FFF 2 5 2012 Ethos TrueBeam Versa HD Radixact Technology CyberKnife Tomotherapy Cyberknife, 2009 MEDICAL / SURGICAL ONCOLOGY Total Robots: 3 SRS/SBRT 2006 Cyclotron Introducing organ-specific working committees – gastrointestinal, head & neck, breast, etc. for better Bone Marrow Transplant DaVinci Robot Versius Robot HoloLens Units data collection & analysis to improve patient outcome 47 www.hcgel.com Tumor Board based Treatment Approach for Patients PIONEER OF TUMOR BOARD IN INDIA Tumor Board Approach Case-specific panel curated involving multiple specialists for ▪ 17+ years of nation wide, Tumor Boards held weekly planning and implementing efficient treatment ▪ Supplemented by multiple local tumor boards Radiologists, Decision Making Body Pathologists Focused committee to shortlist cases to be discussed #1 Tumor Board Special Chairman Psycho Medical Largest Tumor Conveyor Committee Oncologists Oncologists Board in India Cross- consultation Panelists 15 panelists encompassing various specialists 36k+ Radiologists Surgical Radiation Leading Treating and Oncologists Oncologists Total Cases Oncologists Clinicians Pathologists Discussed till Date Participants RIGHT TREATMENT – THE FIRST TIME ITSELF Floor open to question and discuss overall treatment plan 250+ Decision All Other Panelists Oncologist Making Body Clinicians Specialized End-to-end Patient Accuracy and Participation Team Visibility Centric Reliability 48 www.hcgel.com Quality, Research & Academics Ecosystem QUALITY & RESEARCH INITIATIVES Innovation @ H C G HCG ACADEMICS • Grants by Ministry of AYUSH and DST Life of a Laryngectomy person Is marked ONCOLOGY by many problems including no voice • Oral presentations at: Harvard University, ASTRO Meeting, box, breathing through a Trachea-stoma, • DNB ESMO Meeting, Society for Integrative Oncology absence of nasal breathing unable to • Fellowships smell and altered taste & swallow. In order to aid their problems, we at HCG , • Certificate programs SELECT CLINICAL TRIALS supporting our In-house Doctor/inventor introduced Aum - Voice Box. It is an ALLIED HEALTH SERVICES Innovative device made of Silicone, • Genomics: Mutations & treatment response and outcomes helping people to regain their voice at a • B.SC. fractional Cost. • Bachelor: Hospital Administration • Radiation response & Radio sensitivity using Radiomics and Certificate Programs radiogenomics • Whole exome sequencing to identify novel Targets in head NURSING and neck cancers • Diploma • Immunotherapy PDL1 inhibitors, T cell activation, Dendritic • Certificate Programs cell therapy 109* 26* 222* 32* PUBLICATION CLINICAL AUDITS Students Registered For Courses Offered PUBLISHED CONCLUDED Various Courses 49 *For FY22 www.hcgel.com THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Deven Dhruva For updates and specific queries, please visit www.hcgel.com sagar.shroff@sgapl.net / deven.dhruva@sgapl.net or feel free to contact investors@hcgoncology.com Tel: +91 98205 19303 / +91 98333 73300 © 2022 HealthCare Global Enterprises Limited., All Rights Reserved. HCG Logo is trademark of HealthCare Global Enterprises Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners. www.hcgel.com